{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-066062","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2026-05-26T13:26:00+00:00","discovered_at":"2026-05-26T13:27:00.482147+00:00","generated_at":"2026-05-26T13:27:43.981584+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Gain Therapeutics reports Phase 1b extension: GluSph down 81%, 4.8-pt MDS-UPDRS difference","bullets":["16 of 19 Part 1 participants continued into 9-month extension; all 16 remain on study at Day 150.","In participants with elevated baseline CSF GluSph, levels dropped an average of 81% after 90 days.","At Day 150, high-baseline GluSph group showed 4.8-point greater improvement in MDS-UPDRS Parts II+III vs low-baseline group.","Unsolicited patient reports: improved smell/taste (4), balance/gait (4), and sleep (3) after 90 days.","Planned Phase 2 will add UPSIT smell test and Opal wearable gait assessments as endpoints."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-066062","json":"https://secwatch.observer/filing/0001104659-26-066062.json","markdown":"https://secwatch.observer/filing/0001104659-26-066062.md","text":"https://secwatch.observer/filing/0001104659-26-066062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926066062/0001104659-26-066062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926066062/tm2615594d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T13:27:43.981584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}